Paid Clinical Trials Atlanta
Discover 1,572 paid clinical trials in Atlanta. Search by condition or phase to find a research study near you that matches your needs across various therapeutic areas.
A Study of NVL-655 in Patients With Advanced NSCLC and Other Solid Tumors Harboring ALK Rearrangement or Activating ALK Mutation (ALKOVE-1)
Sponsor:
Nuvalent Inc.
Location:
Code:
NCT05384626
Conditions
Locally Advanced Solid Tumor
Metastatic Solid Tumor
Eligibility Criteria
Sex: All
Age: 12+
Healthy Volunteers: Not accepted
Interventions
NVL-655
An Observational Study of Etrasimod in Adult Patients With Moderate to Severe Ulcerative Colitis
Sponsor:
Pfizer
Location:
Code:
NCT06398626
Conditions
Colitis, Ulcerative
Eligibility Criteria
Sex: All
Age: 18 - 64
Healthy Volunteers: Not accepted
Interventions
Etrasimod
A Study to Evaluate Etrasimod Treatment in Adolescents With Ulcerative Colitis
Sponsor:
Pfizer
Location:
Code:
NCT05287126
Conditions
Ulcerative Colitis
Eligibility Criteria
Sex: All
Age: 12 - 17
Healthy Volunteers: Not accepted
Interventions
Etrasimod
Efficacy and Safety of Seralutinib in Adult Subjects With PAH (PROSERA)
Sponsor:
GB002, Inc.
Location:
Code:
NCT05934526
Conditions
Pulmonary Arterial Hypertension
Eligibility Criteria
Sex: All
Age: 18 - 70+
Healthy Volunteers: Not accepted
Interventions
Placebo
Seralutinib
Generic Dry Powder Inhaler
Fasedienol Nasal Spray for the Acute Treatment of Anxiety in Adults With Social Anxiety Disorder (PALISADE-4)
Sponsor:
VistaGen Therapeutics, Inc.
Location:
Code:
NCT06615557
Conditions
Social Anxiety Disorder (SAD)
Eligibility Criteria
Sex: All
Age: 18 - 65
Healthy Volunteers: Not accepted
Interventions
Fasedienol Nasal Spray
Placebo Nasal Spray
An Efficacy and Safety Evaluation of HORIZANT in Adolescents With Moderate-to-Severe Primary RLS
Sponsor:
XenoPort, Inc.
Location:
Code:
NCT02560766
Conditions
RLS
Eligibility Criteria
Sex: All
Age: 13 - 17
Healthy Volunteers: Not accepted
Interventions
HORIZANT 300 mg
HORIZANT 600 mg
Placebo
A Study Evaluating the Efficacy of Budesonide, Glycopyrronium and Formoterol Fumarate Metered Dosed Inhaler on Cardiopulmonary Outcomes in Chronic Obstructive Pulmonary Disease
Sponsor:
AstraZeneca
Location:
Code:
NCT06283966
Conditions
COPD (Chronic Obstructive Pulmonary Disease)
Eligibility Criteria
Sex: All
Age: 40 - 70+
Healthy Volunteers: Not accepted
Interventions
BGF MDI 320/14.4/9.6 μg
GFF MDI 14.4/9.6 μg
A Study to Investigate the Effect on Lung Function of BDA Formulated With a New Propellant (HFO) Compared With an Approved Asthma Treatment (BDA With HFA Propellant) in Participants With Asthma
Sponsor:
AstraZeneca
Location:
Code:
NCT06502366
Conditions
Asthma
Eligibility Criteria
Sex: All
Age: 18+
Healthy Volunteers: Not accepted
Interventions
BDA MDI HFO 160/180 μg
BDA MDI HFA 160/180 μg
Placebo MDI HFA
A Study of Treatment of Inflammation Before Stem Cell Transplant in People With a Primary Immune Regulatory Disorder (PIRD) and/or an Autoinflammatory Condition
Sponsor:
Memorial Sloan Kettering Cancer Center
Location:
Code:
NCT05787574
Conditions
Primary Immune Regulatory Disorder
Autoimmune Lymphoproliferative
Immune System Diseases
Eligibility Criteria
Sex: All
Age: 0 - 70+
Healthy Volunteers: Not accepted
Interventions
Emapalumab
Fludarabine and Dexamethasone
Stem Cell Transplant
Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25
Sponsor:
NRG Oncology
Location:
Code:
NCT05879926
Conditions
Breast Cancer
Eligibility Criteria
Sex: Female
Age: 18 - 60
Healthy Volunteers: Not accepted
Interventions
Ovarian Function Suppression + Aromatase Inhibitor
Adjuvant Chemotherapy + Ovarian Function Suppression